glp-1 drugs and parkinson's disease Signalling as a Therapeutic Avenue in Disease: A Comprehensive Review GLP-1 drug shows little benefit

Choi, Y

and internationally

While their glucose-lowering effects have been well documented for years, recent clinical breakthroughs have shown that these medications can deliver transformative weight loss, often rivalling or even surpassing results from bariatric surgery for certain patients

GLP-1 medications, by contrast, may face supply shortages, require specialty pharmacy fulfillment, and involve navigating prior authorization processes that can delay treatment by weeks

The time interval from surgery to the initiation of GLP-1RAs treatment ranged from 1.5 to 86.7 months, with treatment durations between 4 and 12 months

Given at higher doses than in diabetes treatment, GLP-1 analogues are now routinely licensed for the treatment of obesity, for example high-dose Liraglutide 3 mg daily (43) and Semaglutide 2.4 mg weekly (44)